open access

Vol 23, No 1 (2017)
Review papers
Published online: 2017-05-12
Get Citation

Raynaud’s phenomenon — the clinical picture, treatment and diagnostics

Irena Walecka, Aleksandra Malewska, Marek Roszkiewicz, Marta Wieczorek, Zuzanna Lagun, Elzbieta Szymanska
DOI: 10.5603/AA.2017.0003
·
Acta Angiologica 2017;23(1):29-33.

open access

Vol 23, No 1 (2017)
Review papers
Published online: 2017-05-12

Abstract

Raynaud’s phenomenon is the triphasic phenomenon which consists of sudden paling of distal parts of the body with the following cyanosis and occurance of erythema in the third stage. This phenomenon is a result of peripheral microcirculation disorder and usually appears after exposure to cold. If the RP is a primary, idiopathic (not associated with other diseases) then the other name for this condition is Raynaud’s disease (80% of RP cases). If the RP is secondary to other medical conditions such as connective tissue disorders, arterial alterations etc., then Raynaud’s syndrome is diagnosed and that is why further diagnostics is required in every case of RP.

Abstract

Raynaud’s phenomenon is the triphasic phenomenon which consists of sudden paling of distal parts of the body with the following cyanosis and occurance of erythema in the third stage. This phenomenon is a result of peripheral microcirculation disorder and usually appears after exposure to cold. If the RP is a primary, idiopathic (not associated with other diseases) then the other name for this condition is Raynaud’s disease (80% of RP cases). If the RP is secondary to other medical conditions such as connective tissue disorders, arterial alterations etc., then Raynaud’s syndrome is diagnosed and that is why further diagnostics is required in every case of RP.

Get Citation

Keywords

Raynaud’s phenomenon, capilaroscopy, connective tissue disease, scleroderma

About this article
Title

Raynaud’s phenomenon — the clinical picture, treatment and diagnostics

Journal

Acta Angiologica

Issue

Vol 23, No 1 (2017)

Pages

29-33

Published online

2017-05-12

DOI

10.5603/AA.2017.0003

Bibliographic record

Acta Angiologica 2017;23(1):29-33.

Keywords

Raynaud’s phenomenon
capilaroscopy
connective tissue disease
scleroderma

Authors

Irena Walecka
Aleksandra Malewska
Marek Roszkiewicz
Marta Wieczorek
Zuzanna Lagun
Elzbieta Szymanska

References (20)
  1. Prete M, Fatone MC, Favoino E, et al. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014; 13(6): 655–667.
  2. Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015; 5(3): e006389.
  3. Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun. 2014; 48-49: 60–65.
  4. Shah J, Billington AR, Elston JB, et al. Raynaud's Phenomenon. Eplasty. 2013; 13: ic58.
  5. Ciecierski M, Migdalski M, Jawień A. Choroba i zespół Raynauda. Przew Lek. 2000; 6: 64–66.
  6. Hansen-Dispenza H, Narayanan A, Lisse JR, Oberto-Medina M. Raynaud phenomenon. 2011. Available at:. http://emedicinemedscape.com/article/331197-overview# a0199 (Accessed on July 1, 2013).
  7. Heimovski FE, Simioni JA, Skare TL. Systemic lupus erythematosus and Raynaud's phenomenon. An Bras Dermatol. 2015; 90(6): 837–840.
  8. Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001; 357(9273): 2042–2048.
  9. Overbury R, Murtaugh MA, Fischer A, et al. Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon. Clin Rheumatol. 2015; 34(12): 2135–2140.
  10. Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford). 2010; 49(7): 1374–1382.
  11. Stevens W, Nikpour M, Byron J, et al. Frequency, clinical characteristics and risk factors for digital ulcers in systemic sclerosis. Int Med J. 2011; 41(Suppl 1): 13.
  12. Lim MJ, Kwon SR, Kim SGu, et al. A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases. Rheumatol Int. 2009; 29(6): 685–688.
  13. Kim YH, Ng SW, Seo HS, et al. Classification of Raynaud's disease based on angiographic features. J Plast Reconstr Aesthet Surg. 2011; 64(11): 1503–1511.
  14. Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev. 2012; 11(6-7): A377–A385.
  15. Olsen N. Diagnostic tests in Raynaud's phenomena in workers exposed to vibration: a comparative study. Br J Ind Med. 1988; 45(6): 426–430.
  16. Khanna PP, Maranian P, Gregory J, et al. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010; 69(3): 588–591.
  17. Heidrich H. Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia. Vasa. 2010; 39(1): 33–41.
  18. Cutolo M, Sulli A, Secchi ME, et al. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology (Oxford). 2006; 45 Suppl 4: iv43–iv46.
  19. Goundry B, Bell L, Langtree M, et al. Diagnosis and management of Raynaud's phenomenon. BMJ. 2012; 344: e289.
  20. Parisi S, Peroni CL, Laganà A, et al. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology (Oxford). 2013; 52(6): 1142–1144.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl